Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06220773
PHASE3

A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

Sponsor: Boryung Pharmaceutical Co., Ltd

View on ClinicalTrials.gov

Summary

The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus

Official title: A Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy in Patients With Essential Hypertension and Type 2 Diabetes Mellitus

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

276

Start Date

2024-05-21

Completion Date

2025-04

Last Updated

2024-05-22

Healthy Volunteers

No

Interventions

DRUG

BR1019A

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019B

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019C

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019A-1

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019B-1

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019C-1

Subjects take the investigational products once a day for 12 weeks.

Locations (2)

Severance Hospital

Seoul, South Korea

Severance Hospital

Seoul, South Korea